Shares fall as US Food and Drug panel rejects new Australian biotech drug

By Bianca Hartge-Hazelman
Updated April 24 2014 - 6:08am, first published 5:41am

Shares in Australian pharmaceutical firm QRxPharma have plummeted 80 per cent in a major shareholder revolt after the company failed to win regulatory approval for its painkiller drug MoxDuo to be released in the US.